• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Walker Matthew Alan was granted 14,343,021 shares and bought $15,000,000 worth of shares (1,500,000 units at $10.00)

    2/4/22 8:22:17 PM ET
    $ENVI
    Get the next $ENVI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Walker Matthew Alan

    (Last) (First) (Middle)
    C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC
    200 BOSTON AVENUE, SUITE 3100

    (Street)
    MEDFORD MA 02155

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    GreenLight Biosciences Holdings, PBC [ GRNA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    02/02/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/02/2022 A 14,343,021 A (1) 14,343,021 I by Builders Vision, LLC(2)(3)
    Common Stock 02/02/2022 P 1,500,000 A $10(4) 15,843,021 I by Builders Vision, LLC(2)(3)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    Walker Matthew Alan

    (Last) (First) (Middle)
    C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC
    200 BOSTON AVENUE, SUITE 3100

    (Street)
    MEDFORD MA 02155

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    BUILDERS VISION LLC

    (Last) (First) (Middle)
    110 N.W. 2ND STREET
    SUITE 300

    (Street)
    BENTONVILLE AR 72172

    (City) (State) (Zip)
    Explanation of Responses:
    1. Issued pursuant to the terms of a business combination agreement involving the issuer and GreenLight Biosciences, Inc. in exchange for capital stock previously issued by such company.
    2. Shares owned directly: 3,673,694 by S2G Builders Food & Agriculture Fund III, L.P. ("Fund III"); 2,087,043 by S2G Ventures Fund I, L.P. ("Fund I"); and 8,582,284 by S2G Ventures Fund II, L.P. ("Fund II"). Builders Vision, LLC is Manager of Funds I and II, and General Partner of Fund III, and has power to vote or direct the voting of shares held by the funds. General Partners of Fund I and Fund II are S2G Ventures, LLC and S2G Ventures II, LLC, respectively.
    3. (Continued) Mr. Walker, a director of the Issuer, is a Managing Director at Builders Vision, LLC, the impact platform founded by Lukas T. Walton. By virtue of the foregoing, S2G Ventures LLC, S2G Ventures II, LLC, and Mr. Walton may be deemed to indirectly beneficially own (as defined in Rule 13d-3 of the Exchange Act) the shares of common stock held by the respective funds. Mr. Walker and Mr. Walton each disclaims beneficial ownership of these shares of common stock except to the extent of any pecuniary interest therein.
    4. Amount consists of 1,500,000 shares of common stock issued pursuant to a subscription agreement entered into between the Issuer and S2G Builders Food & Agriculture Fund III, L.P.
    Remarks:
    S2G Advisors, LLC has changed its name to Builders Vision, LLC. Mr. Walker's middle name is spelled Allen, not Alan.
    /s/ David Kennedy, Attorney-in-fact for Matthew Allen Walker 02/04/2022
    /s/ Lisa J. Forbes, as authorized officer of Builders Vision, LLC 02/04/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ENVI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENVI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ENVI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GreenLight Biosciences begins trading today as Nasdaq: GRNA on the closing of its business combination with Environmental Impact Acquisition Corp.

      BOSTON, Feb. 3, 2022 /PRNewswire/ -- GreenLight Biosciences ("GreenLight"), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture, and Environmental Impact Acquisition Corp. (NASDAQ:ENVI) ("ENVI"), a special purpose acquisition company, yesterday announced the closing of their previously announced business combination. In connection with the closing, the company changed its name to GreenLight Biosciences Holdings, public-benefit corporation, with shares of Class A common stock and public warrants

      2/3/22 10:02:00 AM ET
      $ENVI
    • Environmental Impact Acquisition Corporation approval obtained; GreenLight Biosciences set to begin trading under Nasdaq: GRNA on February 3, 2022

      BOSTON, Feb. 2, 2022 /PRNewswire/ -- Environmental Impact Acquisition Corporation (NASDAQ:ENVI), a publicly-traded special purpose acquisition company, announced today that its business combination with Greenlight Biosciences was approved in a shareholder vote held yesterday, with 80.7% of shareholders participating in the vote and 78.6% voting in favor of the combination. Subject to the satisfaction or waiver of the other customary closing conditions, Environmental Impact Acquisition Corp. anticipates closing the business combination today. In connection with the closing, the

      2/2/22 8:58:00 AM ET
      $ENVI
    • GreenLight Biosciences and Germains Seed Technology Partner to Explore Development of World's First dsRNA Seed Treatment to Control Pests

      BOSTON, Jan. 31, 2022 /PRNewswire/ -- GreenLight Biosciences and Germains Seed Technology, an industry leader in seed treatment technologies, today announced a research partnership agreement that could lead to the first commercial use of RNA as a seed treatment to control crop diseases and offer options to farmers looking for innovative solutions. Through the partnership, the two companies will explore synergies between Germains' seed priming and coating technologies and GreenLight's dsRNA expertise and ability to cost-effectively scale manufacturing to protect vegetable crops

      1/31/22 10:40:00 AM ET
      $ENVI

    $ENVI
    Leadership Updates

    Live Leadership Updates

    See more
    • Greenlight Biosciences (ENVI) Adds Two World-Renowned Scientists To Its Scientific Advisory Board

      BOSTON, Nov. 4, 2021 /PRNewswire/ -- GreenLight Biosciences is delighted to announce the appointment of Professor Diane E. Griffin, MD, PhD, and Emmanuel Hanon, DVM, PhD, to its Human Health Scientific Advisory Board. At Johns Hopkins University, Diane Griffin is the Distinguished Service Professor, a professor of Medicine and Neurology at the School of Medicine, and the W. Harry Feinstone professor at the Department of Molecular Microbiology and Immunology at the Bloomberg School of Public Health. She has also been vice president of the U.S. National Academy of Sciences since

      11/4/21 10:02:00 AM ET
      $ENVI
    • GreenLight Biosciences Announces the Appointment of Jennifer Raymond As SVP, CMC and Manufacturing

      BOSTON, Sept. 16, 2021 /PRNewswire/ -- GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, announced the appointment of Jennifer Raymond as SVP, CMC & Manufacturing today. Raymond joins GreenLight from GSK with more than 23 years of experience in the pharmaceutical industry, including 13 years in vaccines development, production, and Quality Assurance, across Merck, Novartis, and GSK. She has comprehensive first-hand experience in both R&D and Operations in small and large scale biological platforms (mammalian, viral, bacterial). Raymond's recent work includes development and launch of specialty biophar

      9/16/21 12:02:00 PM ET
      $ENVI

    $ENVI
    SEC Filings

    See more
    • SEC Form 425 filed by Environmental Impact Acquisition Corp.

      425 - Environmental Impact Acquisition Corp (0001822691) (Subject)

      2/2/22 8:34:52 AM ET
      $ENVI
    • Environmental Impact Acquisition Corp. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Environmental Impact Acquisition Corp (0001822691) (Filer)

      2/2/22 8:32:05 AM ET
      $ENVI
    • SEC Form 425 filed by Environmental Impact Acquisition Corp.

      425 - Environmental Impact Acquisition Corp (0001822691) (Subject)

      1/28/22 9:10:59 AM ET
      $ENVI

    $ENVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Walker Matthew Alan was granted 14,343,021 shares and bought $15,000,000 worth of shares (1,500,000 units at $10.00)

      4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

      2/4/22 8:22:17 PM ET
      $ENVI
    • SEC Form 3 filed by new insider Walker Matthew Alan

      3 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

      2/4/22 8:20:21 PM ET
      $ENVI
    • SEC Form 4 filed by Keefe Susan

      4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

      2/4/22 8:01:51 PM ET
      $ENVI

    $ENVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Environmental Impact Acquisition Corp.

      SC 13G - Environmental Impact Acquisition Corp (0001822691) (Subject)

      7/6/21 5:19:57 PM ET
      $ENVI